Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 7/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16915921 | 0.81 | CNR2 (0.34) | PTGDR2CNR2 | |
| SCHEMBL20596677 | 0.78 | SRC (0.41) | SRCPTGDR2PTGDRHTR6IMPDH2 | |
| SCHEMBL4616627 | 0.71 | PTGDR2 (0.55) | PTGDR2HTR6 | |
| SCHEMBL20657207 | 0.70 | KDM4E (0.43) | SRCHTR6IMPDH2ALDH1A1LMNA | |
| SCHEMBL20673174 | 0.68 | KDM1A (0.43) | KDM1A | |
| SCHEMBL20657190 | 0.67 | KDM1A (0.62) | KDM1A | |
| SCHEMBL20595090 | 0.67 | KDM1A (0.53) | KDM1A | |
| SCHEMBL20673178 | 0.66 | PPARG (0.44) | SRCHTR6IMPDH2ALDH1A1HPGD | |
| SCHEMBL20595084 | 0.65 | HTR6 (0.52) | HTR6ALDH1A1LMNAHPGD | |
| SCHEMBL29605086 | 0.64 | PTGDR2 (0.54) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032641-A | Substituted 5-cyanoindole compounds and uses thereof | 诺华股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | KDM1A, KDM5A, KDM1B | SRC 2006/4885PTGDR2 3382/4885PTGDR 3422/4885 |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | KDM1A, KDM5A, KDM1B | SRC 2006/4885PTGDR2 3382/4885PTGDR 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.